Chimeric Animal Inflammation Treatment Innovation

The original patent disclosed methods for treating and preventing immune response and inflammation in chimeric animals after birth. However, these methods were not tailored to specific, narrow markets or unique operational environments. The present invention addresses this limitation by providing specialized variations and niche solutions for treating inflammation in chimeric animals after birth, thereby expanding the applicability of the original invention.

The novelty of the present invention lies in the adaptation of the original patent's methods for treating and preventing immune response and inflammation in chimeric animals after birth to specialized environments, such as high-security needs, disaster relief, or extreme weather conditions. The inventive step is the recognition of the need for tailored solutions for these specific markets and the development of compositions and methods that address these needs.

Alternative embodiments of the present invention include the use of different anti-inflammatory agents or immunosuppressive agents, or the administration of these agents through different routes or at different stages of the chimeric animal's development. Variations of the invention may also include the use of different types of xenogeneic or allogeneic cells, or the development of new tolerance-inducing agents.

The present invention has significant commercial potential in the fields of biotechnology, veterinary medicine, and disaster relief. The invention's ability to provide specialized solutions for treating inflammation in chimeric animals after birth in high-security environments, disaster relief scenarios, or extreme weather conditions addresses a significant unmet need in these markets.